Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
M. Sundell, A.-C. Spetz Holm, M. Fredrikson, M. Hammar, M. Hoffmann & J. Brynhildsen. (2022) Pulmonary embolism in menopausal hormone therapy: a population-based register study. Climacteric 25:6, pages 615-621.
Read now
Read now
Placido Llaneza, Joaquim Calaf, Ana Rosa Jurado, Nicolas Mendoza, Borja Otero, Francisco Quereda, Rafael Sánchez-Borrego & Daniel Lubian. (2018) What do TSECs provide in the menopausal hormone therapy?. Gynecological Endocrinology 34:10, pages 826-832.
Read now
Read now
Santiago Palacios & Andrea Mejía. (2016) Progestogen safety and tolerance in hormonal replacement therapy. Expert Opinion on Drug Safety 15:11, pages 1515-1525.
Read now
Read now
K. Kibbey & A. Vincent. (2011) Premature surgical menopause and Factor V Leiden heterozygosity: case report and literature review. Climacteric 14:1, pages 185-188.
Read now
Read now
Susan R Davis & Fiona Jane. (2010) Drugs for the treatment of menopausal symptoms. Expert Opinion on Pharmacotherapy 11:8, pages 1329-1341.
Read now
Read now
Articles from other publishers (18)
S. V. Mironova & N. A. Koziolova. (2022) The use of menopausal hormone therapy in women at high cardiovascular risk. "Arterial’naya Gipertenziya" ("Arterial Hypertension") 28:4, pages 357-375.
Crossref
Crossref
Andrea R Genazzani, Patrizia Monteleone, Andrea Giannini & Tommaso Simoncini. (2021) Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice. Human Reproduction Update 27:6, pages 1115-1150.
Crossref
Crossref
O. V. Yakushevskaya. (2021) Continuous combined low-dose hormone replacement therapy in perimenopause: an algorithm of choice. Meditsinskiy sovet = Medical Council:3, pages 113-118.
Crossref
Crossref
T. F. Tatarchuk. (2020) From menarche to menopause. REPRODUCTIVE ENDOCRINOLOGY:56, pages 18-22.
Crossref
Crossref
Sophia Tsiligiannis, Bettina C. Wick-Urban, Jan van der Stam & John C. Stevenson. (2020) Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms. Maturitas 139, pages 20-26.
Crossref
Crossref
V. I. Podzolkov, A. E. Bragina & N. M. Podzolkovа. (2019) Menopausal hormone therapy and heart disease prevention: desired or valid?. Cardiovascular Therapy and Prevention 18:3, pages 94-106.
Crossref
Crossref
Clare Oliver-Williams, Marija Glisic, Sara Shahzad, Elizabeth Brown, Cristina Pellegrino Baena, Mahmuda Chadni, Rajiv Chowdhury, Oscar H Franco & Taulant Muka. (2019) The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Human Reproduction Update 25:2, pages 257-271.
Crossref
Crossref
Fuminori Taniguchi, Ikuko Ota, Yumiko Iba, Toshiko Toda, Yukiko Tagashira, Yorie Ohata, Hiroko Kurioka, Yusuke Endo, Hiroshi Sunada, Hisashi Noma, Yukihiro Azuma & Tasuku Harada. (2019) The efficacy and safety of dydrogesterone for treatment of dysmenorrhea: An open-label multicenter clinical study. Journal of Obstetrics and Gynaecology Research 45:1, pages 168-175.
Crossref
Crossref
Denise Rovinski, Ramon B. Ramos, Tayane M. Fighera, Gislaine K. Casanova & Poli Mara Spritzer. (2018) Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. Thrombosis Research 168, pages 83-95.
Crossref
Crossref
A. A. Smetnik. (2017) MENOPAUSAL HORMONE THERAPY WITH DYDROGESTERONE: ASPECTS OF EFFICACY AND SAFETY OF ULTRA-LOW DOSES. Medical Council:2, pages 92-99.
Crossref
Crossref
Marianne Canonico. (2015) Hormone therapy and risk of venous thromboembolism among postmenopausal women. Maturitas 82:3, pages 304-307.
Crossref
Crossref
Fumitake Ito, Hiroshi Tatsumi, Taisuke Mori, Izumi Suganuma, Yukiko Tanaka, Aya Sasaki, Seiki Matsuo, Koichi Iwasa & Jo Kitawaki. (2014) Medroxyprogesterone Acetate Enhances Monocyte-Endothelial Interaction Under Flow Conditions by Stimulating the Expression of Cell Adhesion Molecules. The Journal of Clinical Endocrinology & Metabolism 99:6, pages 2188-2197.
Crossref
Crossref
John C. Stevenson, Nicholas Panay & Claire Pexman-Fieth. (2013) Oral estradiol and dydrogesterone combination therapy in postmenopausal women: Review of efficacy and safety. Maturitas 76:1, pages 10-21.
Crossref
Crossref
Frank Z. StanczykJanet P. Hapgood, Sharon Winer & Daniel R. MishellJr.Jr.. (2013) Progestogens Used in Postmenopausal Hormone Therapy: Differences in Their Pharmacological Properties, Intracellular Actions, and Clinical Effects. Endocrine Reviews 34:2, pages 171-208.
Crossref
Crossref
X.-D. Fu, S. Garibaldi, S. Gopal, K. Polak, G. Palla, S. Spina, P. Mannella, A. R. Genazzani, A. D. Genazzani & T. Simoncini. (2011) Dydrogesterone exerts endothelial anti-inflammatory actions decreasing expression of leukocyte adhesion molecules. Molecular Human Reproduction 18:1, pages 44-51.
Crossref
Crossref
Florence Tremollieres, Marc Brincat, C. Tamer Erel, Marco Gambacciani, Irene Lambrinoudaki, Mette H. Moen, Karin Schenck-Gustafsson, Svetlana Vujovic, Serge Rozenberg & Margaret Rees. (2011) EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas 69:2, pages 195-198.
Crossref
Crossref
Val?rie Oli?Marianne Canonico & Pierre-Yves Scarabin. (2011) Postmenopausal hormone therapy and venous thromboembolism. Thrombosis Research 127, pages S26-S29.
Crossref
Crossref
Valérie Olié, Marianne Canonico & Pierre-Yves Scarabin. (2010) Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Current Opinion in Hematology 17:5, pages 457-463.
Crossref
Crossref